ArticleActa epileptologica2026
Serum insulin-like growth factor-1 and its association with epilepsy risk and cognitive function.
Article in Acta epileptologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundInsulin-like growth factor 1 (IGF-1) has neurotrophic and neuroprotective properties, but its relationship with epilepsy risk and cognitive outcomes remains unclear. We investigated whether serum IGF-1 was associated with incident epilepsy and cognitive performance in a large population-based cohort.
methodsWe performed a prospective analysis of the UK Biobank including 466,857 participants with baseline serum IGF-1 measurements. Incident epilepsy was identified from hospital records and self-report. Associations with epilepsy risk were assessed using prespecified Cox proportional hazards models, restricted cubic splines, and sensitivity analyses. Cross-sectional and longitudinal analyses were used to examine cognitive outcomes.
resultsOver more than 15 years of follow-up, 4,532 participants developed incident epilepsy. Higher serum IGF-1 was consistently associated with a lower risk of incident epilepsy; in the primary model, each 1 nmol/L increase was associated with a lower hazard of incident epilepsy (HR = 0.978, 95% CI 0.973-0.984). The association was nonlinear and L-shaped, with a steeper increase in risk at lower IGF-1 concentrations and an apparent plateau above approximately 20 nmol/L. Per-standard-deviation, quartile-based, lagged, and alcohol-frequency sensitivity analyses showed similar results. In cross-sectional analyses of participants with epilepsy at baseline, higher IGF-1 was nominally associated with faster reaction time and better prospective memory, but neither association remained significant after false discovery rate correction. Exploratory longitudinal analyses in the epilepsy subgroup were limited by sample size and did not show significant cross-lagged associations. In the full cohort, higher baseline IGF-1 was associated with better subsequent performance in several cognitive domains, although these findings were not epilepsy-specific.
conclusionsLower serum IGF-1 was independently associated with a higher risk of incident epilepsy in this large population-based cohort. Evidence for cognitive associations was more limited, with only nominal cross-sectional findings in baseline epilepsy and exploratory, non-epilepsy-specific longitudinal signals. These results support further investigation of circulating IGF-1 as a candidate biomarker and biologically relevant pathway rather than as evidence of a causal or therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.